Novel therapeutic strategies for patients with triple-negative breast cancer

被引：21
|
作者：
Zhang, Jun-Fei [1 ]
Liu, Jia [1 ,2 ]
Wang, Yu [1 ,2 ]
Zhang, Bin [1 ,2 ]
机构：
[1] Inner Mongolia Univ Nationalities, Affiliated Hosp, Tongliao, Inner Mongolia, Peoples R China
[2] Inner Mongolia Univ Nationalities, Med Chem & Pharmacol Inst, 1742 Holin He St, Tongliao 028007, Inner Mongolia, Peoples R China
来源：
ONCOTARGETS AND THERAPY | 2016年 / 9卷
基金：
中国国家自然科学基金;
关键词：
therapeutic strategies; TNBC; targeted agents; TUMOR-INFILTRATING LYMPHOCYTES; GROWTH-FACTOR RECEPTOR; PATHOLOGICAL COMPLETE RESPONSE; NEOADJUVANT CHEMOTHERAPY; AFRICAN-AMERICAN; PHASE-II; CARBOPLATIN; PACLITAXEL; INIPARIB; SURVIVAL;
D O I：
10.2147/OTT.S105716
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Triple-negative breast cancer (TNBC) represents a very heterogeneous group of breast diseases. Currently, the backbone of therapy for TNBC is mainly chemotherapy as there are no effective specific targeted agents approved to treat TNBC. Despite initial responses to chemotherapy, resistance frequently and rapidly develops and metastatic TNBC has a poor prognosis. Therefore, new targeted strategies are, accordingly, urgently needed. This article discusses the recent developments in targeted agents explored for TNBC, aiming to offer novel therapeutic strategies that can potentially assist in designing personalized therapeutics in the future as well as provide the basis for further research in an attempt to target TNBC.
引用
收藏
页码：6519 / 6528
页数：10
相关论文
共 50 条
  • [31] Evolving Treatment Strategies for Triple-Negative Breast Cancer
    Telli, Melinda
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (5.5): : 652 - 654
  • [32] Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacists' Perspective
    Li, Shuanghe
    Bao, Chongyang
    Huang, Lingli
    Wei, Ji-Fu
    [J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (20)
  • [33] Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies
    Xiong, Nating
    Wu, Heming
    Yu, Zhikang
    [J]. FRONTIERS IN ONCOLOGY, 2024, 14
  • [34] Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
    Nandini, Dey
    Jennifer, Aske
    Pradip, De
    [J]. PHARMACEUTICALS, 2021, 14 (05)
  • [35] Therapeutic delivery of siRNA for the management of breast cancer and triple-negative breast cancer
    Sai, Boya Manasa
    Dinakar, Yirivinti Hayagreeva
    Kumar, Hitesh
    Jain, Rupshee
    Kesharwani, Sharyu
    Kesharwani, Siddharth S.
    Mudavath, Shyam lal
    Ramkishan, Ajmeer
    Jain, Vikas
    [J]. THERAPEUTIC DELIVERY, 2024,
  • [36] Therapeutic strategies for metastatic triple negative breast cancer
    Takano, Toshimi
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [37] Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer
    Boscolo Bielo, Luca
    Trapani, Dario
    Curigliano, Giuseppe
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (07) : 789 - 801
  • [38] Emerging Novel Therapeutics in Triple-Negative Breast Cancer
    Lyons, Tomas G.
    Traina, Tiffany A.
    [J]. BREAST CANCER METASTASIS AND DRUG RESISTANCE: CHALLENGES AND PROGRESS, 2ND EDITION, 2019, 1152 : 377 - 399
  • [39] SLC22A17 as a novel therapeutic target for triple-negative breast cancer
    Kunnumakkara, A. B.
    Thakur, K. K.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S139 - S139
  • [40] Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer
    Shao, Claire
    Anand, Vivek
    Andreeff, Michael
    Battula, Venkata Lokesh
    [J]. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 2022, 1508 (01) : 35 - 53
12345